PET imaging of insulin-like growth factor type 1 receptor expression with a 64Cu-labeled Affibody molecule

Amino Acids

Volumn 47, Issue 7, 2015, Pages 1409-1419

  Su, Xinhui ^a,b   Cheng, Kai ^b   Liu, Yang ^b   Hu, Xiang ^b   Meng, Shuxian ^b   Cheng, Zhen ^b  

^a ZHONGSHAN HOSPITAL OF XIAMEN UNIVERSITY   (China)

^b STANFORD UNIVERSITY   (United States)

Author keywords

64Cu; Affibody; IGF 1R; NOTA; PET

Indexed keywords

CONTRAST MEDIUM; COPPER 64; COPPER NOTA Z CU 64 CONJUGATE; SOMATOMEDIN C; UNCLASSIFIED DRUG; COPPER; HYBRID PROTEIN; PEPTIDE FRAGMENT; RADIOPHARMACEUTICAL AGENT; SOMATOMEDIN C RECEPTOR; STAPHYLOCOCCUS PROTEIN A; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG UPTAKE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMAGE QUALITY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR LOCALIZATION; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; METABOLISM; NUDE MOUSE; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALIA; MUS;

ANIMALS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; COPPER RADIOISOTOPES; GLIOBLASTOMA; HUMANS; MICE, NUDE; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, IGF TYPE 1; RECOMBINANT FUSION PROTEINS; STAPHYLOCOCCAL PROTEIN A; TISSUE DISTRIBUTION;

EID: 84930540625     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-015-1975-4     Document Type: Article

References (30)

1. 64Cu-labeled bifunctional chelate-bombesin conjugates. Bioconjug Chem 22:1729-1735
2. Arcaro A (2013) Targeting the insulin-like growth factor-1 receptor in human cancer. Front Pharmacol 4:30
3. 64Cu-labeled Affibody molecules for imaging of HER2 expressing tumors. Mol Imaging Biol 12:316-324
4. 111In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin). Nucl Med Biol 35:645-653
5. Fleuren ED, Versleijen-Jonkers YM, van de Luijtgaarden AC, Molkenboer-Kuenen JD, Heskamp S, Roeffen MH, van Laarhoven HW, Houghton PJ, Oyen WJ, Boerman OC, van der Graaf WT (2011) Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507. Clin Cancer Res 17:7693-7703
6. Friedman M, Nordberg E, Höidén-Guthenberg I, Brismar H, Adams GP, Nilsson FY, Carlsson J, Stahl S (2007) Phage display selection of affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng Des Sel 20:189-199
7. Gong Y, Yao E, Shen R, Goel A, Arcila M, Teruya-Feldstein J, Zakowski MF, Frankel S, Peifer M, Thomas RK, Ladayi M, Pao W (2009) High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 4:e7273
8. Haisa M (2013) The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer. J Int Med Res 41:253-264
9. 111in-labeled F(ab')(2) and fab fragments of the monoclonal antibody R1507. Mol Pharm 9:2314-2321
10. Li J, Lundberg E, Vernet E, Larsson B, Höidén-Guthenberg I, Gräslund T (2010) Select-ion of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor. Biotechnol Appl Biochem 55:99-109
11. 64Cu labeled Affibody protein. Bioconjug Chem 21:947-954
12. 18F-labeled Affibody molecule. J Nucl Med 53:1110-1118
13. 99mTc-ZIGF1R:4551-GGGC Affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression. Amino Acids 47:303-315
14. Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY (2007) Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 13:2795-2803
15. Orlova A, Hofström C, Strand J, Varasteh Z, Sandstrom M, Andersson K, Tolmachev V, Gräslund T (2013) [99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours. Eur J Nucl Med Mol Imaging 40:439-449
16. Ozkan EE (2011) Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer andanti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Mol Cell Endocrinol 344:1-24
17. Pollak M (2008) Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 8:915-927
18. Pollak M (2012) The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin Cancer Res 18:40-50
19. 64Cu-NOTA-8-Aoc-BBN (7-14)NH2] targeting vector for positron-emission tomography imaging of gastrinreleasing peptide receptor-expressing tissues. Proc Natl Acad Sci USA 104:12462-12467
20. Ren G, Webster JM, Liu Z, Zhang R, Miao Z, Liu H, Gambhir SS, Syud FA, Cheng Z (2012) In vivo targeting of HER2-positive tumor using 2-helix affibody molecules. Amino Acids 43:405-413
21. Rolleman EJ, de Valkema JM R, Kooij PP, Krenning EP (2003) Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 30:9-15
22. Singh P, Alex JM, Bast F (2014) Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer. Med Oncol 31:805
23. 18F-labeled Affibodies for PET imaging of EGFR positive tumors. Mol Pharm 11:3947-3956
24. Tolmachev V, Stone-Elander S, Orlova A (2010) Current approaches to the use of radiolabeled tyrosine kinase-targeting drugs for patient stratification and treatment response monitoring: prospects and pitfalls. Lancet Oncol 11:992-1000
25. 111In-DOTA-ZIGF1R:4551. J Nucl Med 53:90-97
26. van Eerd JE, Vegt E, Wetzels JF, Russel FG, Masereeuw R, Corstens FH, Oyen WJ, Boerman OC (2006) Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. J Nucl Med 47:528-533
27. Vegt E, van Eerd JE, Eek A, Oyen WJ, Wetzels JF, de Jong M, Russel FG, Masereeuw R, Gotthardt M, Boerman OC (2008) Reducing renal uptake of radiolabeled peptides using albumin fragments. J Nucl Med 49:1506-1511
28. Xue M, Cao X, Zhong Y, Kuang D, Liu X, Zhao Z, Li H (2012) Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives. Curr Pharm Des 18:2901-2913
29. Zha J, O'Brien C, Savage H, Huw LY, Zhong F, Berry L, Lewis Philips GD, Luis E, Cavet G, X H, Amler LC, Lackner MR (2009) Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther 8:2110-21121
30. 64Cu-labeled monoclonal anti-body: NOTA is superior to DOTA. PLoS One 6:e28005